Zaleplon 10mg Capsules Under Fasting Conditions
Information source: Teva Pharmaceuticals USA
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Zaleplon 10 mg Capsules (Drug); Sonata® 10 mg Capsules (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Teva Pharmaceuticals USA Official(s) and/or principal investigator(s): So Ran Hong, M.D., Principal Investigator, Affiliation: Novum Pharmaceutical Research Services
Summary
The objective of this study was to compare the relative bioavailability of Zaleplon 10 mg
Capsules manufactured by TEVA Pharmaceuticals USA and Sonata® 10 mg Capsules manufactured by
Wyeth Laboratories in healthy, non-smoking adults under fasting conditions.
Clinical Details
Official title: A Relative Bioavailability Study of Zaleplon 10mg Capsules Under Fasting Conditions
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label
Primary outcome: Cmax - Maximum Observed ConcentrationAUC0-Inf - Area Under the Concentration-Time Curve From Time Zero to Infinity (Extrapolated) AUC0-t - Area Under the Concentration-Time Curve From Time Zero to Time of Last Non-Zero Concentration (Per Participant)
Detailed description:
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- non-smokers
- at least 18 years of age
- BMI of 30 or less
Exclusion Criteria:
- Subjects with a significant recent history of chronic alcohol consumption (past 2
years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular
disease, tuberculosis, epilepsy, asthma (past 5 years), diabetes, psychosis or
glaucoma will not be eligible for this study.
- Subjects whose clinical laboratory test values are outside the reference ranges may
be retested at the discretion of the clinical investigator. If the clinical values
are outside the range on retesting, the subject will not be eligible to participate
in the study unless the clinical investigator deems the result to not be significant.
- Subjects who have a history of allergic responses to the class of drug being tested
will be excluded from the study. Subjects with intolerance to alcohol or other CNS
depressants should not participate in this study.
- Subjects who use tobacco in any form will not be eligible to participate in the
study. Three months abstinence is required.
- All subjects will have urine samples assayed for the presence of drugs of abuse as
part of the clinical laboratory screening procedures and at each dosing period
check-in. Subjects found to have urine concentrations of any of the tested drugs will
not be allowed to participate.
- Subjects should not have donated blood and/or plasma for at least thirty (30) days
prior to the first dosing of the study.
- Subjects who have taken any investigational drug within thirty (30) days prior to the
first dosing of the study will not be allowed to participate.
- Female subjects who are pregnant, breast-feeding, or who are likely to become
pregnant during the study will not be allowed to participate. Female subjects of
child bearing potential must either abstain from sexual intercourse or use a reliable
barrier method (e. g. condom, IUD) of contraception during the course of the study
(first dosing until last blood collection) or they will not be allowed to
participate. Female subjects who have used hormonal oral contraceptives within 14
days of dosing or implanted or injected hormonal contraceptives within 180 days of
dosing will not be allowed to participate.
- All female subjects will be screened for pregnancy at check-in each study period.
Subjects with positive or inconclusive results will be withdrawn from the study.
- Subjects who do not tolerate venipuncture will not be allowed to participate.
Locations and Contacts
Novum Pharmaceutical Research Services, Houston, Texas 77040, United States
Additional Information
Starting date: February 2004
Last updated: July 6, 2009
|